JPWO2020102603A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020102603A5
JPWO2020102603A5 JP2021526460A JP2021526460A JPWO2020102603A5 JP WO2020102603 A5 JPWO2020102603 A5 JP WO2020102603A5 JP 2021526460 A JP2021526460 A JP 2021526460A JP 2021526460 A JP2021526460 A JP 2021526460A JP WO2020102603 A5 JPWO2020102603 A5 JP WO2020102603A5
Authority
JP
Japan
Prior art keywords
antibody
epitope
cdrs
independently selected
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513043A (ja
JP2022513043A5 (https=
JP7695881B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061567 external-priority patent/WO2020102603A1/en
Publication of JP2022513043A publication Critical patent/JP2022513043A/ja
Publication of JPWO2020102603A5 publication Critical patent/JPWO2020102603A5/ja
Publication of JP2022513043A5 publication Critical patent/JP2022513043A5/ja
Priority to JP2024199831A priority Critical patent/JP2025026923A/ja
Application granted granted Critical
Publication of JP7695881B2 publication Critical patent/JP7695881B2/ja
Priority to JP2026003911A priority patent/JP2026065087A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526460A 2018-11-14 2019-11-14 操作されたｃｄ２５ポリペプチドおよびその使用 Active JP7695881B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024199831A JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用
JP2026003911A JP2026065087A (ja) 2018-11-14 2026-01-13 操作されたｃｄ２５ポリペプチドおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862767431P 2018-11-14 2018-11-14
US62/767,431 2018-11-14
US201962902334P 2019-09-18 2019-09-18
US62/902,334 2019-09-18
PCT/US2019/061567 WO2020102603A1 (en) 2018-11-14 2019-11-14 Engineered cd25 polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024199831A Division JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用

Publications (4)

Publication Number Publication Date
JP2022513043A JP2022513043A (ja) 2022-02-07
JPWO2020102603A5 true JPWO2020102603A5 (https=) 2023-06-14
JP2022513043A5 JP2022513043A5 (https=) 2023-06-14
JP7695881B2 JP7695881B2 (ja) 2025-06-19

Family

ID=70731914

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021526460A Active JP7695881B2 (ja) 2018-11-14 2019-11-14 操作されたｃｄ２５ポリペプチドおよびその使用
JP2024199831A Pending JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用
JP2026003911A Pending JP2026065087A (ja) 2018-11-14 2026-01-13 操作されたｃｄ２５ポリペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024199831A Pending JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用
JP2026003911A Pending JP2026065087A (ja) 2018-11-14 2026-01-13 操作されたｃｄ２５ポリペプチドおよびその使用

Country Status (6)

Country Link
US (1) US12441803B2 (https=)
EP (1) EP3880698A4 (https=)
JP (3) JP7695881B2 (https=)
CN (1) CN113646330A (https=)
CA (1) CA3120102A1 (https=)
WO (1) WO2020102603A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
EP3976083A4 (en) * 2019-05-31 2023-07-12 iBio, Inc. MACHINE LEARNING BASED DEVICE FOR THE DEVELOPMENT OF MESO-SCALE PEPTIDES, AND METHOD AND SYSTEM THEREOF
WO2021119261A1 (en) * 2019-12-10 2021-06-17 Homodeus, Inc. Generative machine learning models for predicting functional protein sequences
CN116745318A (zh) * 2020-11-10 2023-09-12 斯克里普斯研究学院 用于阿片样物质治疗的抗体
US20240096443A1 (en) * 2020-12-01 2024-03-21 Ibio, Inc. Generalized Scaffolds for Polypeptide Display and Uses Thereof
US20250179196A1 (en) * 2021-07-30 2025-06-05 Janssen Biotech, Inc. Materials and methods of making or using il-23r binding proteins
CN114384245B (zh) * 2022-03-24 2022-06-24 江苏美克医学技术有限公司 新型冠状病毒s-rbd蛋白和n蛋白双表位识别的联检试剂盒及其应用
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279057C (zh) * 2002-07-12 2006-10-11 马菁 重组的抗cd25单克隆抗体、其编码序列及应用
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
CN107129524B (zh) 2007-09-25 2023-11-21 田园温室气体研究有限公司 用于抑制微生物细胞的疫苗和疫苗组分
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
FI2970398T3 (fi) 2013-03-13 2024-08-06 Us Health Rsv f -prefuusioproteiineja ja niiden käyttö
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2016040110A1 (en) 2014-09-10 2016-03-17 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
WO2016179212A1 (en) 2015-05-05 2016-11-10 Albert Einstein College Of Medicine, Inc. Antibody therapeutics against filovirus infections and uses thereof
WO2018089829A1 (en) * 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
CN110856446A (zh) * 2017-04-18 2020-02-28 阿法姆海外股份有限公司 抗pd-l1抗体及其用途
JP7464530B2 (ja) * 2018-03-28 2024-04-09 ブリストル－マイヤーズ スクイブ カンパニー インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
EP3976083A4 (en) 2019-05-31 2023-07-12 iBio, Inc. MACHINE LEARNING BASED DEVICE FOR THE DEVELOPMENT OF MESO-SCALE PEPTIDES, AND METHOD AND SYSTEM THEREOF

Similar Documents

Publication Publication Date Title
RU2757813C2 (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
AU2002368077B2 (en) Super humanized antibodies
US20210230269A1 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
TW201945396A (zh) 最佳化抗-tl1a抗體
AU2017387041B2 (en) Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof
JP6949012B2 (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
RU2010119450A (ru) Антитело против bst2
JP2023530663A (ja) 抗ＴＧＦβ抗体及びその治療的使用
BR112020003628A2 (pt) anticorpo anti-pacap
JP6358763B2 (ja) インターロイキン−２０に対するヒト化抗体および炎症性疾患のための治療
JPWO2020102603A5 (https=)
JP6755513B2 (ja) 抗スクレロスチン抗体、その抗原結合フラグメントおよびその医薬用途
RU2015129655A (ru) Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела
CN111699006B (zh) Il17抗体及其应用
JP2022534080A (ja) 新規の抗ｂ型肝炎ウイルス抗体及びその使用
JPWO2022226342A5 (https=)
CN120435502A (zh) 抗ige抗体
JP2004517636A (ja) Ｂ型肝炎ウイルスの表面抗原ｓに対するヒト化抗体及びその製造方法
CN117247452A (zh) 抗胃泌素的单克隆抗体及其用途
JP7762311B2 (ja) 抗成長分化因子１５の抗体分子及びその応用
CN114426580B (zh) 抗csf-1r抗体及其产品、方法和用途
JPWO2021055408A5 (https=)
RU2841957C1 (ru) Сконструированные антитела против il-2
CN117843784A (zh) 抗人cd73抗体或其抗原结合片段及其应用